Edition:
United States

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

3.76EUR
11:35am EDT
Change (% chg)

€0.05 (+1.21%)
Prev Close
€3.71
Open
€3.72
Day's High
€3.78
Day's Low
€3.72
Volume
64,792
Avg. Vol
141,207
52-wk High
€4.19
52-wk Low
€2.64

Chart for

About

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and... (more)

Overall

Beta: 1.73
Market Cap(Mil.): €295.98
Shares Outstanding(Mil.): 77.58
Dividend: --
Yield (%): --

Financials

  VLS.PA Industry Sector
P/E (TTM): -- 235.76 33.88
EPS (TTM): -0.10 -- --
ROI: -5.51 -5.45 13.21
ROE: -8.62 -6.94 15.18

BRIEF-Valneva FY Net Loss Narrows To 11.5 Million Euros

* EXPECTS DOUBLE-DIGIT PRODUCT SALES GROWTH TO CONTINUE IN 2018

Mar 22 2018

BRIEF-Valneva Says No Safety Concerns Associated With VLA15 In Any Treatment Group‍​

* NO SAFETY CONCERNS ASSOCIATED WITH VLA15 IN ANY TREATMENT GROUP‍​

Mar 19 2018

BRIEF-Valneva Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate VLA15

* VALNEVA REPORTS POSITIVE PHASE I INTERIM RESULTS FOR ITS LYME VACCINE CANDIDATE VLA15 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 19 2018

BRIEF-Valneva Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate Vla15

* REG-VALNEVA REPORTS POSITIVE PHASE I INTERIM RESULTS FOR ITS LYME VACCINE CANDIDATE VLA15

Mar 19 2018

BRIEF-Valneva Initiates Phase I Clinical Study Of Vaccine Candidate Against Chikungunya

* REG-VALNEVA INITIATES PHASE I CLINICAL STUDY TO EVALUATE ITS SINGLE-SHOT VACCINE CANDIDATE AGAINST CHIKUNGUNYA

Mar 13 2018

BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus

* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

Feb 26 2018

BRIEF-Valneva ‍Total Revenues Up At 109.8 Million Euros

* ‍TOTAL REVENUES OF EUR 109.8 MILLION IN 2017 (2016 - EUR 97.9 MILLION)​

Feb 15 2018

Earnings vs. Estimates